Cited by 49Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer

Open access
Kitakaze, Masatoshi, Uemura, Mamoru, Hara, Tomoaki, Chijimatsu, Ryota, Motooka, Daisuke, Hirai, Toshiro, Konno, Masamitsu, Okuzaki, Daisuke +10 more·2023·British Journal of Cancer

Abstract

Background: Tissue-resident memory T (Trm) cells are associated with cytotoxicity not only in viral infection and autoimmune disease pathologies but also in many cancers. Tumour-infiltrating CD103+ Trm cells predominantly comprise CD8 T cells that express cytotoxic activation and immune checkpoint molecules called exhausted markers. This study aimed to investigate the role of Trm in colorectal cancer (CRC) and characterise the cancer-specific Trm. Methods: Immunochemical staining with anti-CD8 and anti-CD103 antibodies for resected CRC tissues was used to identify the tumour-infiltrating Trm cells. The Kaplan–Meier estimator was used to evaluate the prognostic significance. Cells immune to CRC were targeted for single-cell RNA-seq analysis to characterise cancer-specific Trm cells in CRC. Results: The number of CD103+/CD8+ tumour-infiltrating lymphocytes (TILs) was a favourable prognostic and predictive factor of the overall survival and recurrence-free survival in patients with CRC. Single-cell RNA-seq analysis of 17,257 CRC-infiltrating immune cells revealed a more increased zinc finger protein 683 (ZNF683) expression in cancer Trm cells than in noncancer Trm cells and in high-infiltrating Trm cells than low-infiltrating Trm in cancer, with an upregulated T-cell receptor (TCR)- and interferon-γ (IFN-γ) signalling-related gene expression in ZNF683+ Trm cells. Conclusions: The number of CD103+/CD8+ TILs is a prognostic predictive factor in CRC. In addition, we identified the ZNF683 expression as one of the candidate markers of cancer-specific Trm cells. IFN-γ and TCR signalling and ZNF683 expression are involved in Trm cell activation in tumours and are promising targets for cancer immunity regulation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-023-02202-4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TRM cells can be identified by upregulation of specific transcription factors such as HOBIT, RUNX3, and BLIMP-1, which lead to transcriptional reprogramming to downregulate tissue egress genes and upregulate tissue retention markers.

    “Additionally, T RM cells can be identified by the upregulation of specific transcription factors such as HOBIT (homolog of Blimp-1 in T cells), RUNX3 (runt-related transcription factor 3), and BLIMP-1 (B lymphocyte-induced maturation protein-1), which lead to transcriptional reprogramming to downregulate tissue egress genes and upregulate tissue retention markers. 295-298”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [298]

    The Results section (‘The characteristics of ZNF683+ Trm’) identifies HOBIT/ZNF683 as a transcription factor and a reported core gene of Trm cells; the Discussion also identifies it as homologous to BLIMP-1. Our copy does not establish RUNX3 or BLIMP-1 upregulation as ways to identify Trm cells, or say that these factors downregulate tissue-egress genes and upregulate retention markers. No page numbers are available in the indexed passages. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kitakaze, M., Uemura, M., Hara, T., Chijimatsu, R., Motooka, D., Hirai, T., Konno, M., Okuzaki, D., Sekido, Y., Hata, T., Ogino, T., Takahashi, H., Miyoshi, N., Ofusa, K., Mizushima, T., Eguchi, H., Doki, Y., & Ishii, H.
Affiliations
  • The University of Osaka (JP)
  • Center of Medical Innovation and Translational Research, The University of Osaka (JP)
  • Research Institute for Microbial Diseases, The University of Osaka (JP)
  • IDEA Consultants, Inc. (Japan) (JP)
Corresponding author
Ishii, Hideshi
Venue
British Journal of Cancer
Published
2023-03-03
Volume
128
Issue
10
Pages
1828-1837
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4323043053
Cited by
49
References
48
Citations by year
2026: 13 · 2025: 23 · 2024: 13
FWCI
5.98
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (20H00541, 18KK0251, 19K22658, 21K19526, 22H03146, 22K19559, 16H06279 (PAGS), 22H04925 (PAGS))
  • Mitsubishi Foundation (2021)
  • Japan Agency for Medical Research and Development (17cm0106414h0002, JP21lm0203007)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tissue-resident memory T cells, colorectal cancer, tumor-infiltrating lymphocytes, prognostic factors, interferon-gamma signaling, T cell receptor signaling, T cell exhaustion, cancer immunotherapy targets
MeSH terms
Memory T Cells, Humans, Immunologic Memory, Prognosis, Transcription Factors, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review